Influence of Atorvastatin on Psoriasis Severity and Endothelial Function

Launched by SHMUEL FUCHS · Feb 3, 2012

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients older than 20 years
• • Patients with psoriasis of at least 3-years duration
• • Current moderate to severe psoriatic disease (PASI ≥12, IGA≥3)
• • Statin-naïve patients
• • No history of cardiovascular disease (ischemic heart disease, peripheral vascular disease or cerebrovascular disease)
• • LDL levels
• • LDL level \> 70 mg% and \< 160 mg% in low risk patients (defined as having none or a single risk factor\*)
• • LDL \> 70 mg% and \< 130 mg% in moderate risk patients (defined as the presence of 2 or more risk factors\*)
• • LDL \> 70 mg% and \< 100 mg% in patients with type II diabetes
• • hsCRP ≥ 1 mg/l \* Risk factors: smoking, hypertension (blood pressure \> 140/90 or current treatment with blood pressure lowering agents, HDL \< 40 mg%, family history of premature coronary artery disease in a first degree relative younger than 45 (men) or 55 (women) and obesity (BMI ≥ 30).
• Exclusion Criteria:
• • Current statin therapy
• • Patents with Atrial Fibrillation
• • Elevated liver enzymes (\> X3 ULN)
• • History of statin-induced liver enzyme elevation
• • Elevated CPK levels (\> X3 ULN)
• • History of myopathy including statin-induced
• • Severe chronic renal failure (GFR \<30 ml/min)
• • Pregnant or breast-feeding women
• • Individuals at risk for poor protocol, or medication compliance
• • Patients with life-expectancy of less than 2 years
• • Patients who are currently participating in another clinical trial
• • Other current active inflammatory and/or infectious conditions
• • Sensitivity to any of atorvastatin ingredients
• • Concomitant drug therapy, taken on a regular basis, which may interact with Atorvastatin